The invention provides an application of a compound ainsliaidimer A in preparing a
nucleolus transcription factor inhibitor medicament. The inventor carries out experiments of detecting activity of NF (nuclear factor)-kappa B by adopting EMSA (electrophoretic mobility shift
assay), detecting differences of NF-kappa B in cells by immunochemical luminescent
assay, detecting expression of the NF-kappa in ainsliaidimer A acting HL-60 cells by a
Western blot method, detecting expression of
apoptosis related
protein in
lymphoma cell CA46
cell after action of the ainsliaidimer A by the
Western blot method, detecting influence of the ainsliaidimer A on HL-60
cell secretion VEGF (
vascular endothelial growth factor) and the like. Results prove that the ainsliaidimer A has a good inhibition effect to the activity of the NF-kappa B abnormally activated by
tumor cells, so that, the compound ainsliaidimer A serving as an
active component can be used for preparing a
nucleolus transcription factor inhibitor medicament. The medicament can be used as novel application for treating
leukemia, autoimmune diseases, renal diseases, heart cerebrovascular diseases, various inflammations, neurodegenerative disorders and eye disorders of animals and humans caused by abnormally activation of the NF-kappa B factor, thereby providing a new method for treating the diseases and disorders, and having higher clinical application value.